Indoco Remedies receives final USFDA approval for rivaroxaban tablets
Rivaroxaban is used to treat venous thromboembolism
Rivaroxaban is used to treat venous thromboembolism
EBITDA before special items decreases to €4.08 billion (7.4%)
Bayer expects 2025 to be the most difficult year of its turnaround
The product will be launched in Q1FY26
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The company has received five final approvals
Subscribe To Our Newsletter & Stay Updated